In Vitro Modeling of Natural Killer Cell Cytotoxicity to Inform Personalized ALS Therapeutics

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Background:

• Natural killer (NK) cells may cause motor neuron death in amyotrophic lateral sclerosis (ALS).
• Tofacitinib, an FDA-approved JAK/STAT inhibitor, may reduce NK cell cytotoxicity.
• Understanding NK cell involvement in ALS is crucial for developing targeted therapies.

Purpose of the Study:

• To confirm tofacitinib's efficacy in suppressing NK cell cytotoxicity in ALS.
• To determine if immune cell profiles can predict response to tofacitinib.
• To assess the correlation between NK cell cytotoxicity and ALS progression.

Main Methods:

• Primary NK cells were isolated from ALS patients and healthy controls.
• NK cell cytotoxicity was measured via co-culture assays with and without tofacitinib.
• Immune cell profiles were generated using flow cytometry (154 markers) and correlated with NK cell activity and treatment response.

Main Results:

• Tofacitinib significantly reduced NK cell cytotoxicity in both ALS participants and healthy controls.
• Immune cell profiles correlated with tofacitinib response.
• NK cell cytotoxicity was lower in ALS patients than controls and did not correlate with disease progression.

Conclusions:

• Tofacitinib effectively suppresses NK cell cytotoxicity, supporting its potential therapeutic role in ALS.
• Immune profiling shows promise for identifying patient subgroups likely to benefit from tofacitinib.
• Further investigation is required to elucidate the precise role and temporal contribution of NK cells in ALS pathogenesis.